01
Overview
Lurex Bio is an early-stage biotechnology company focused on the discovery and development of novel therapeutic agents for the treatment of infectious diseases and oncology. The company leverages its proprietary chemical libraries and screening technologies to identify small molecule candidates with unique mechanisms of action. Currently, Lurex Bio is advancing several programs through the pre-clinical stage, aiming to address significant unmet medical needs in global health. The company's research efforts are centered on optimizing lead compounds for improved efficacy and safety profiles before entering clinical trials.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Lurex Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lurex Bio.